Back to search
FDAFDA · Food and drugs·Recall number D-0754-2023

HyperLyte CR Injection, 500 mL bag, Rx only, Central Admixture Pharmacy Services, 6580 Snowdrift Road, Allentown, PA 18106, NDC 71285-8094-1, code 7128580941.

Published May 31, 2023 · Recall initiated: April 28, 2023

Summary

FDA records drug Class II recall D-0754-2023, published May 31, 2023 and initiated April 28, 2023. Recalling firm: Central Admixture Pharmacy Services, Inc.; Status: Terminated; Reported quantity: 554 bags; Lot: Lot # 37-874236, Exp 06/20/2023; 37-878694, Exp 07/10/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Central Admixture Pharmacy Services, Inc.
Distributor
Nationwide in the USA.
Lot
Lot # 37-874236, Exp 06/20/2023; 37-878694, Exp 07/10/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was HyperLyte CR Injection, 500 mL bag, Rx only, Central Admixture Pharmacy Services, 6580 Snowdrift Road, Allentown, PA 18106, NDC 71285-8094-1, code 7128580941. recalled?

Yes. FDA published recall D-0754-2023 on May 31, 2023. Reported hazard: Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail